William E. Rote Sells 8,951 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 8,951 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $19.78, for a total value of $177,050.78. Following the transaction, the senior vice president now directly owns 95,719 shares of the company’s stock, valued at $1,893,321.82. This trade represents a 8.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $21.21 on Thursday. The firm has a market capitalization of $1.66 billion, a PE ratio of -4.66 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.86. The company’s 50 day simple moving average is $18.74 and its 200 day simple moving average is $15.51.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently modified their holdings of the company. Aigen Investment Management LP bought a new position in Travere Therapeutics during the third quarter valued at about $170,000. Oppenheimer & Co. Inc. acquired a new stake in Travere Therapeutics in the 3rd quarter valued at about $673,000. FMR LLC boosted its position in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after purchasing an additional 31,772 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Travere Therapeutics by 30.2% in the 3rd quarter. Two Sigma Advisers LP now owns 720,400 shares of the company’s stock worth $10,078,000 after purchasing an additional 167,100 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Travere Therapeutics by 3.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after purchasing an additional 64,744 shares in the last quarter.

Wall Street Analysts Forecast Growth

TVTX has been the subject of a number of recent research reports. Bank of America upped their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Guggenheim lifted their price objective on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright upped their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald assumed coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating on the stock. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.